Skip to main content

Table 2 Time to disease progression and PFS by drug category and treatment line – from chart review

From: Treatment patterns and real world clinical outcomes in ER+/HER2- post-menopausal metastatic breast cancer patients in the United States

Variable First-line treatment n # Censored obs.a Median (months) 95% confidence interval p-valueb
Lower limit Upper limit  
Time to disease progression on first-line therapy (months) from start of first-line therapy Aromatase inhibitors 103 8 12.0 10.0 13.1  
Chemotherapy 25 13 7.9 6.0 8.3  
Other 50 8 11.9 7.0 17.3 0.3563
Progression- free survival on second line therapy (months) from start of second-line therapy Aromatase inhibitors 103 16 7.4 5.7 8.4  
Chemotherapy 25 8 7.3 5.1 11.2  
Other 50 19 8.1 7.0 12.0 0.1047
Progression- free survival on third-line therapy (months) from start of third-line therapy Aromatase inhibitors 55 23 8.0 3.4 12.0  
Chemotherapy 11 6 9.0 1.4 NE  
Other 20 7 5.2 4.0 14.1 0.9176
  1. PFS Progression-free survival; NE Not Estimable
  2. aCensored patients are patients who have not had an event of disease progression, either because they dropped out from the trial for reasons other than disease progression or because they had not progressed when data were cut-off. b log rank test